Magenta Therapeutics, Inc. Contracts & Agreements

71 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended
Stock Agreements
Magenta Therapeutics, Inc.
2024
Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan
Bonus & Incentive Agreements
Magenta Therapeutics, Inc.
2024
Separation Agreement, dated May 12, 2023, by and between Magenta Therapeutics, Inc. and Lisa Olson
Separation Agreements
Magenta Therapeutics, Inc.
2024
Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended
Magenta Therapeutics, Inc.
2024
Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan
Stock Agreements
Magenta Therapeutics, Inc.
2024
Form of Stock Option Agreement for Executives under the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan
Bonus & Incentive Agreements
Magenta Therapeutics, Inc.
2024
Amendment to Offer Letter, dated September 11, 2023, by and between Dianthus Therapeutics OpCo, Inc. and Simrat Randhawa
Magenta Therapeutics, Inc.
2024
Separation Agreement, dated February 7, 2023, by and between Magenta Therapeutics, Inc. and Jason Gardner
Separation Agreements
Magenta Therapeutics, Inc.
2024
Separation Agreement, dated September 11, 2023, by and between Magenta Therapeutics, Inc. and Thomas Beetham
Separation Agreements
Magenta Therapeutics, Inc.
2024
Form of Pre-Funded Warrant
Warrant Agreements
Magenta Therapeutics, Inc.
2024
Securities Purchase Agreement, dated January 22, 2024, by and between Dianthus Therapeutics, Inc. and each purchaser identified on Annex A thereto
Purchase Agreements
Magenta Therapeutics, Inc.
2024
Form of Registration Rights Agreement
Registration Rights Agreements
Magenta Therapeutics, Inc.
2024
Separation Agreement, dated September 11, 2023, by and between Magenta Therapeutics, Inc. and Stephen Mahoney
Separation Agreements
Magenta Therapeutics, Inc.
2023
Contingent Value Rights Agreement, dated September 11, 2023, by and between the Company and the Rights Agent
Magenta Therapeutics, Inc.
2023
Registration Rights Agreement, dated September 11, 2023, by and among the Company, OpCo and certain parties thereto
Registration Rights Agreements
Magenta Therapeutics, Inc.
2023
Form of Indemnification Agreements for Directors of the Company
Indemnification Agreements
Magenta Therapeutics, Inc.
2023
Form of Indemnification Agreements for Officers of the Company
Indemnification Agreements
Magenta Therapeutics, Inc.
2023
Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan
Bonus & Incentive Agreements
Magenta Therapeutics, Inc.
2023
Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Marino Garcia
Magenta Therapeutics, Inc.
2023
Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Ryan Savitz
Magenta Therapeutics, Inc.
2023
Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Edward Carr
Magenta Therapeutics, Inc.
2023
Form of Pre-Funded Warrant of the Company
Warrant Agreements
Magenta Therapeutics, Inc.
2023
Sublease Termination and Release Agreement by and between the Registrant and Novartis Institutes for Biomedical Research, Inc., dated as of March 31, 2023
Lease Agreements
Magenta Therapeutics, Inc.
2023
Agreement and Plan of Merger, dated as of May 2, 2023, by and among Magenta Therapeutics, Inc., Dio Merger Sub, Inc. and Dianthus Therapeutics, Inc
Merger Agreements
Magenta Therapeutics, Inc.
2023
Amendment No. 1 to Stockholder Rights Agreement, dated as of May 2, 2023, by and between Magenta Therapeutics, Inc. and Computershare Trust Company, N.A., as Rights Agent
Trust Agreements
Magenta Therapeutics, Inc.
2023
Form of Dianthus Support Agreement
Magenta Therapeutics, Inc.
2023
Form of Contingent Value Rights Agreement
Magenta Therapeutics, Inc.
2023
Form of Lock-Up Agreement
Magenta Therapeutics, Inc.
2023
Form of Magenta Support Agreement
Magenta Therapeutics, Inc.
2023
Amendment No. 3, effective as of August 1, 2022, to the Exclusive Research, Development Option and License Agreement by and between the Registrant and Heidelberg Pharma Research...
License Agreements
Magenta Therapeutics, Inc.
2022
Amended and Restated Employment Agreement by and between the Registrant and Thomas Beetham, effective May 2, 2022
Employment Agreements
Magenta Therapeutics, Inc.
Biotechnology
MA
2022
Amended and Restated Employment Agreement by and between the Registrant and David Nichols, effective May 2, 2022
Employment Agreements
Magenta Therapeutics, Inc.
2022
Amended and Restated Employment Agreement by and between the Registrant and Stephen Mahoney, effective March 3, 2022
Employment Agreements
Magenta Therapeutics, Inc.
Biotechnology
MA
2022
Amended and Restated Employment Agreement by and between the Registrant and Jason Gardner, effective March 3, 2022
Employment Agreements
Magenta Therapeutics, Inc.
2022
Master Services Agreement, dated as of May 22, 2019, by and between the Registrant and Heidelberg Pharma Research GmbH
Services Agreements
Magenta Therapeutics, Inc.
Biotechnology
NY
2022
Securities Purchase Agreement, dated as of May 12, 2021, among Magenta Therapeutics, Inc. and each purchaser party thereto
Purchase Agreements
Magenta Therapeutics, Inc.
Biotechnology
NY
2021
Employment Agreement by and between the Registrant and Stephen F. Mahoney, effective November 9, 2020
Employment Agreements
Magenta Therapeutics, Inc.
2021
Second Amendment to Sublease Agreement, dated as of August 19, 2020, by and between the Registrant and Novartis Institutes for BioMedical Research, Inc
Lease Agreements
Magenta Therapeutics, Inc.
2021
Amendment #1 to Collaboration Agreement, effective as of December 31, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program...
Collaboration Agreements
Magenta Therapeutics, Inc.
2021
Amendment #3 to Project Rider #1, effective as of December 16, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a...
Collaboration Agreements
Magenta Therapeutics, Inc.
Biotechnology
2021
Amendment #2 to Project Rider #1, effective as of November 13, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a...
Collaboration Agreements
Magenta Therapeutics, Inc.
Biotechnology
2021
First Amendment to Employment Agreement, executed as of October 14, 2020, by and between the Registrant and John C. Davis, Jr., M.D
Employment Agreements
Magenta Therapeutics, Inc.
Biotechnology
2020
Underwriting Agreement, dated as of June 24, 2020, by and among Magenta Therapeutics, Inc. and Goldman Sachs & Co. LLC and Cowen and Company, LLC, as representatives of the...
Underwriting Agreements
Magenta Therapeutics, Inc.
2020
Underwriting Agreement, dated as of June 24, 2020, by and among Magenta Therapeutics, Inc. and Goldman Sachs & Co. LLC and Cowen and Company, LLC, as representatives of the...
Underwriting Agreements
Magenta Therapeutics, Inc.
2020
Description of Securities of the Registrant
Magenta Therapeutics, Inc.
2020
Amendment #1 to Project Rider #3, effective as of August 26, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be...
Collaboration Agreements
Magenta Therapeutics, Inc.
Biotechnology
2019
Amendment, effective as of July 4, 2019, pursuant to the Exclusive Research, Development Option and License Agreement by and between the Registrant and Heidelberg Pharma Research...
License Agreements
Magenta Therapeutics, Inc.
2019
2019 Employee Stock Purchase Plan
Stock Agreements
Magenta Therapeutics, Inc.
2019
Form of Underwriting Agreement
Underwriting Agreements
Magenta Therapeutics, Inc.
Biotechnology
NY
2019
Letter Agreement, effective as of February 28, 2019, by and between the Registrant and Heidelberg Pharma Research GmbH relating to the Exclusive Research, Development Option and...
License Agreements
Magenta Therapeutics, Inc.
Biotechnology
2019
First Amendment to Sublease by and between Novartis Institutes for BioMedical Research, Inc. and the Registrant, dated as of December 13, 2018
Lease Agreements
Magenta Therapeutics, Inc.
2019
Project Rider #3, effective as of September 6, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10,...
Collaboration Agreements
Magenta Therapeutics, Inc.
Biotechnology
2019
Project Rider #2, effective as of June 26, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10, 2017
Collaboration Agreements
Magenta Therapeutics, Inc.
2019
Amendment #1 to Project Rider #1, effective as of December 6, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as...
Collaboration Agreements
Magenta Therapeutics, Inc.
Biotechnology
2019
Agreement, dated as of May 31, 2018, by and between the Registrant and The Richmond Group, Inc
Magenta Therapeutics, Inc.
2018
Master Development and Manufacturing Agreement by and between Bachem Americas, Inc. and the Registrant, dated as of February 13, 2018
Development Agreements
Magenta Therapeutics, Inc.
Biotechnology
NY
2018
Specimen Common Stock Certificate
Stock Agreements
Magenta Therapeutics, Inc.
Biotechnology
2018
2018 Stock Option and Incentive Plan and forms of award agreements thereunder
Bonus & Incentive Agreements
Magenta Therapeutics, Inc.
Biotechnology
DE
2018
First Amendment to Sublease Agreement, dated as of May 30, 2018, by and between the Registrant and Surface Oncology, Inc
Lease Agreements
Magenta Therapeutics, Inc.
2018
2016 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder
Stock Agreements
Magenta Therapeutics, Inc.
2018
Form of Underwriting Agreement
Underwriting Agreements
Magenta Therapeutics, Inc.
Biotechnology
NY
2018
Second Amended and Restated Investors Rights Agreement by and among the Registrant and certain of its stockholders dated April 2, 2018
Investor Rights Agreements
Magenta Therapeutics, Inc.
2018
Exclusive Research, Development Option and License Agreement by and between Heidelberg Pharma Research GmbH and the Registrant, dated as of March 1, 2018
License Agreements
Magenta Therapeutics, Inc.
Biotechnology
NY
2018
Senior Executive Cash Incentive Bonus Plan
Bonus & Incentive Agreements
Magenta Therapeutics, Inc.
Biotechnology
2018
Form of Employment Agreement
Employment Agreements
Magenta Therapeutics, Inc.
2018
Form of Indemnification Agreement
Indemnification Agreements
Magenta Therapeutics, Inc.
2018
License Agreement by and between President and Fellows of Harvard College and the Registrant, dated as of November 2, 2016
License Agreements
Magenta Therapeutics, Inc.
Biotechnology
MA
2018
License Agreement by and between Novartis International Pharmaceutical Ltd. and the Registrant, dated as of April 3, 2017
License Agreements
Magenta Therapeutics, Inc.
Biotechnology
NY
2018
Collaboration Agreement by and between Be The Match BioTherapies and the Registrant, dated as of November 10, 2017
Collaboration Agreements
Magenta Therapeutics, Inc.
Biotechnology
MN
2018
Clinical Trial Agreement by and between Regents of the University of Minnesota and the Registrant, dated as of January 22, 2018
Magenta Therapeutics, Inc.
2018
Master Development and Manufacturing Agreement by and between Bachem Americas, Inc. and the Registrant, dated as of February 13, 2018
Development Agreements
Magenta Therapeutics, Inc.
2018